Clinical use of topoisomerase I inhibitors in anticancer treatment

Carlos Rodriguez-Galindo, Kristine Radomski, Clinton F. Stewart, Wayne Furman, Victor M. Santana, Peter J. Houghton

Research output: Contribution to journalReview article

42 Scopus citations

Abstract

The camptothecin analogs topotecan and irinotecan have shown to be among the most effective anticancer agents and, as S-phase specific agents, their antitumor effect is maximized when they are administered in protracted schedules. The documented activity as single agents in many adult and pediatric malignancies has been followed by their use in combination with other anticancer agents. These studies have shown promising results, and have placed topotecan and irinotecan in the first line treatment for some malignancies. However, studies to better determine the optimal schedules and sequence of combinations are needed.

Original languageEnglish (US)
Pages (from-to)385-402
Number of pages18
JournalMedical and Pediatric Oncology
Volume35
Issue number4
DOIs
StatePublished - Oct 13 2000

    Fingerprint

Keywords

  • Children
  • Irinotecan
  • Topoisomerase I inhibitors
  • Topotecan

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this